Upper Digestive Cancer

Upper digestive cancer includes, but is not limited to, cancers of the pancreas, stomach, esophagus, gastroesophageal (GE) junction, gall bladder, and bile ducts. 

They are among the most aggressive cancers and can be difficult to identify early because many patients initially present with nonspecific symptoms, leading to delays in diagnosis and poor survival outcomes. Symptoms often overlap with more common and benign gastrointestinal conditions like dyspepsia, gastritis, or reflux. However, it is important to know patterns and symptom progression, especially in patients over 50 or those with relevant risk factors.

Despite significant mortality, no standardized screening exists for these cancers. Early diagnosis often depends on clinical vigilance and timely evaluation of presenting symptoms. Given the nonspecific nature of early symptoms, a careful and thorough approach is essential, particularly in individuals over 50 or those with known risk factors.

Navigation Toolkit for Suspected Upper Digestive Cancer

The navigation toolkit has been created to provide information on the diagnostic and referral process for patients with suspected Upper Digestive cancer. These algorithms and accompanying resources have been co-designed with a clinical group of experts in surgery, and oncology. 

•    Pancreatic, Biliary Tract and Gallbladder Toolkit
•    Esophageal, Stomach and Gastroesophageal Toolkit

Risk Factors

Several modifiable and non-modifiable risk factors are associated with upper digestive cancers.
 

General Risk Factors:
 

• Age >50
• Family or personal history of GI or other cancers
• Smoking and alcohol consumption
• Obesity and poor dietary habits (processed/red meats, low fiber)
   

Cancer-Specific Risks:
 

• Esophageal Cancer: GERD, Barrett’s esophagus, smoking, alcohol
• Stomach Cancer: Helicobacter pylori infection, chronic gastritis, high salt diet
• Pancreatic Cancer: Diabetes mellitus, chronic pancreatitis, BRCA mutations
• Cholangiocarcinoma: Primary sclerosing cholangitis (PSC), liver flukes, choledochal cysts
• Gallbladder Cancer: Gallstones, porcelain gallbladder, chronic inflammation

 

While some symptoms may appear mild at first, certain clinical features should raise concern. If any of the following are present, they should be considered alarming signs that warrant urgent investigation and referral:
 

• Progressive dysphagia especially when patients describe food sticking in the throat or chest
• Unexplained weight loss particularly if it is rapid or accompanied by appetite changes
• Persistent upper abdominal or epigastric pain not responding to initial treatment or getting worse
• Nausea or vomiting that does not improve, or is associated with early satiety
• New or worsening anorexia, or a general aversion to eating
• Painless jaundice, dark urine, or pale stools, which may indicate biliary obstruction
• GERD or indigestion symptoms that persist despite adequate treatment (e.g., PPIs)
• Unexplained iron deficiency anemia, particularly in the absence of overt bleeding
• Fatigue or malaise, when accompanied by any of the above
   

These symptoms should prompt further workup including bloodwork, imaging, and endoscopic evaluation as appropriate without delay.

Treatment

Early and Advanced Stage Upper GI Cancer

Management of upper gastrointestinal cancers is based on tumor type, location, stage, and the patient’s overall health status. Treatment is coordinated through multidisciplinary teams at Saskatchewan’s cancer centres and typically involves a combination of surgery, systemic therapy, and supportive care.
 

Treatment of Early-Stage Disease

Patients with localized or potentially resectable disease may be eligible for curative-intent treatment. This typically involves:
 

• Surgical resection of the tumor (e.g., esophagectomy, gastrectomy, Whipple procedure, or liver resection)
• Neoadjuvant (Pre-operative) therapy (chemotherapy or chemoradiation) may be used before surgery to shrink tumors, treat microscopic disease, and improve outcomes
• Adjuvant (Post-operative) chemotherapy is often recommended postoperatively to treat microscopic disease and to reduce the risk of recurrence
   

Examples by cancer type:
 

• Esophageal & GE junction cancers:
  • Treated with preoperative chemoradiation or peri-operative (pre- and post-surgery) chemotherapy, followed by esophagectomy
  • Postoperative immunotherapy may be offered for patients with residual disease
• Gastric cancer:
  • Standard treatment includes perioperative chemotherapy (pre- and post-surgery)
  • Surgical options depend on tumor location and include subtotal or total gastrectomy
• Pancreatic and biliary tract cancers:
  • Neoadjuvant chemotherapy (e.g., FOLFIRINOX or gemcitabine-based) may be used for borderline resectable disease
  • Resectable tumors are treated with surgery (e.g., Whipple procedure or gallbladder/liver resection), followed by adjuvant chemotherapy

Patients are typically reviewed at a multidisciplinary cancer conference to determine the optimal sequence and modality of treatment.
 

Treatment of Advanced or Metastatic Disease

When cancer is unresectable or metastatic, the focus shifts to disease control, symptom management, and quality of life. Treatment plans are guided by tumor type, molecular characteristics, and patient performance status.
 

• Systemic therapy is the mainstay of treatment:
  • Combination chemotherapy regimens (e.g., FOLFOX, FOLFIRINOX, gemcitabine/cisplatin)
  • Targeted therapy for HER2-positive or FGFR2/IDH1-mutated tumors
  • Immunotherapy for PD-L1 positive or MSI-high tumors
• Palliative procedures may include:
  • Stenting for esophageal or duodenal obstruction
  • Biliary drainage (e.g., ERCP with stent)
  • Radiation therapy for local symptom control (e.g., pain, bleeding, dysphagia)
• Supportive care is integrated throughout and may include:
  • Dietitian support, pancreatic enzyme replacement (PERT), and symptom-directed therapies
  • Early referral to palliative care to support symptom management and advance care planning

Treatment decisions are made in collaboration with the patient and care team, with consideration for functional status, comorbidities, and patient preferences.

Signs and Symptoms

Some symptoms may appear mild at first, certain clinical features should raise concerns. If any of the following are present, they should be considered signs that warrant urgent investigation and referral including bloodwork, imaging and endoscopic evaluation:
 

• Progressive dysphagia especially when patients describe food sticking in the throat or chest
• Unexplained weight loss particularly if it is rapid or accompanied by appetite changes
• Persistent upper abdominal or epigastric pain not responding to initial treatment or getting worse
• Nausea or vomiting that does not improve, or is associated with early satiety
• New or worsening anorexia, or a general aversion to eating
• Painless jaundice, dark urine, or pale stools, which may indicate biliary obstruction
• GERD or indigestion symptoms that persist despite adequate treatment (e.g., PPIs)
• Unexplained iron deficiency anemia, particularly in the absence of overt bleeding
• Fatigue or malaise, when accompanied by any of the above

Clinical Presentation

Upper digestive cancers are difficult to identify early because patients initially present with nonspecific symptoms. These symptoms overlap with more common and benign gastrointestinal conditions, such as dyspepsia, gastritis, or reflux. It is important to know patterns and symptom progression especially in patients over 50 or those with relevant risk factors. 

Referral Pathway for Suspected Upper GI Cancers 

For patients with clinical symptoms suggestive of an upper gastrointestinal malignancy, referral should be directed to the appropriate surgical specialist based on the likely site of disease. This ensures timely investigation and surgical assessment when cancer is suspected but not yet confirmed.
 

• Pancreatic or bile duct lesions
  Refer to a hepatopancreatobiliary (HPB) surgeon. These referrals are appropriate for patients with painless jaundice, pancreatic masses, bile duct dilatation, or other imaging findings concerning for malignancy.
   
• Esophageal stomach or GE junction lesions
  Refer to a thoracic surgeon. Progressive dysphagia, weight loss, or abnormal findings on endoscopy (e.g., mass, stricture) should prompt referral.

Initial Assessment

In patients with persistent upper digestive cancer symptoms, an initial workup in primary care may include:
 

• Complete blood count (CBC) – to assess for anemia, particularly iron deficiency
• Liver function tests – to evaluate for cholestasis or hepatic involvement
• Renal and electrolyte panel – especially relevant if symptoms include vomiting or poor intake
• Amylase and lipase – where pancreatic pathology is considered
   

Findings that suggest structural abnormalities or underlying malignancy typically warrant further diagnostic imaging or specialist referral.
 

 

Imaging and Diagnostic Investigations Guided by Clinical Presentations
 

• Abdominal ultrasound: often the first imaging modality for suspected hepatobiliary pathology
• Contrast-enhanced CT scan: useful for characterizing masses and assessing local or distant spread
• Esophagogastroduodenoscopy (EGD): indicated in the presence of dysphagia, refractory upper digestive cancer symptoms, weight loss, or iron deficiency anemia
• MRCP or ERCP: considered when biliary obstruction or intra-/extrahepatic ductal involvement is suspected
• Endoscopic ultrasound (EUS): valuable in the evaluation of pancreatic or biliary tract lesions 
   

Referral for endoscopic evaluation should be considered when first-line investigations are inconclusive and symptoms persist, or when concerning features are present.

Treatment Overview: Early and Advanced Stage Upper GI Cancers

Management of upper gastrointestinal cancers is based on tumor type, location, stage, and the patient’s overall health status. Treatment is coordinated through multidisciplinary teams at our Cancer Agency centres and typically involves a combination of surgery, systemic therapy and supportive care.

 

Treatment of Early-Stage Disease
 

Patients with localized or potentially resect able disease may be eligible for curative-intent treatment. This involves:
 

• Surgical resection of the tumor (e.g., esophagectomy, gastrectomy, Whipple procedure, or liver resection)
• Neoadjuvant (Pre-operative) therapy (chemotherapy or chemoradiation) may be used before surgery to shrink tumors, treat microscopic disease, and improve outcomes
• Adjuvant (post-operative) chemotherapy is often recommended postoperatively to treat microscopic disease and to reduce the risk of recurrence

 

Examples by cancer type:
 

• Esophageal & GE junction cancers:
  • Treated with preoperative chemoradiation or peri-operative (pre- and post-surgery) chemotherapy, followed by esophagectomy
  • Postoperative immunotherapy may be offered for patients with residual disease
• Gastric cancer:
  • Standard treatment includes perioperative chemotherapy (pre- and post-surgery)
  • Surgical options depend on tumor location and include subtotal or total gastrectomy
• Pancreatic and biliary tract cancers:
  • Neoadjuvant chemotherapy (e.g., FOLFIRINOX or gemcitabine-based) may be used for borderline resect able disease
  • Resect able tumors are treated with surgery (e.g., Whipple procedure or gallbladder/liver resection), followed by adjuvant chemotherapy

Patients are reviewed at a multidisciplinary cancer conference to determine the optimal sequence and modality of treatment.

 

Treatment of Advanced or Metastatic Disease
 

When cancer is unresectable or metastatic, the focus shifts to disease control, symptom management and quality of life. Treatment plans are guided by tumor type, molecular characteristics and patient performance status.
 

• Systemic therapy is the mainstay of treatment:
  • Combination chemotherapy regimens (e.g., FOLFOX, FOLFIRINOX, gemcitabine/cisplatin)
  • Targeted therapy for HER2-positive or FGFR2/IDH1-mutated tumors
  • Immunotherapy for PD-L1 positive or MSI-high tumors
• Palliative procedures may include:
  • Stenting for esophageal or duodenal obstruction
  • Biliary drainage (e.g., ERCP with stent)
  • Radiation therapy for local symptom control (e.g., pain, bleeding, dysphagia)
• Supportive care is integrated throughout and may include:
  • Dietitian support, pancreatic enzyme replacement (PERT), and symptom-directed therapies
  • Early referral to palliative care to support symptom management and advance care planning

Treatment decisions are made in collaboration with the patient and care team, with consideration for functional status, comorbidities, and patient preferences.

Surveillance After Treatment for Upper Gastrointestinal Cancer

For patients treated with curative intent (e.g., surgery with or without chemotherapy or chemoradiation), post-treatment surveillance plays a role in detecting recurrence, managing treatment-related complications and monitoring nutritional and metabolic status.
 

Most recurrences occur within the first three years, often between scheduled visits, so patient education and prompt evaluation of new or concerning symptoms are essential. Some localized recurrences may be amenable to curative treatment, symptom-driven interventions and early palliative care are also critical.

 

Recommended Follow-Up Schedule
 

• Every 3–6 months, during the first three years
• Every 6–12 months, during the next two years
• Annually thereafter, as clinically appropriate

 

Surveillance Components
 

• History and physical examination at each visit
   
• Laboratory tests, as clinically indicated:
  • CBC, liver function tests, serum chemistry
  • Tumor markers (e.g., CEA, CA19-9) if initially elevated
• Imaging (e.g., CT scans) based on symptoms or clinical suspicion of recurrence
   
• Endoscopy for patients with:
  • Ongoing dysphagia or suspected local recurrence (esophageal/gastric cancers)
  • Anastomotic strictures requiring dilation post-esophagectomy
• Nutritional and metabolic monitoring:
  • Dietary counseling to address weight loss, malabsorption, or specific dietary challenges
  • Vitamin B12 supplementation for those with proximal or total gastrectomy
  • Pancreatic enzyme replacement therapy (PERT) for patients with exocrine insufficiency, especially post-pancreatic resection
  • Fasting blood glucose and/or HbA1c to assess for new-onset diabetes, particularly after pancreaticoduodenectomy

Pilot Program for Rapid Diagnosis Pathway for Upper Digestive Cancers

The Saskatchewan Cancer Agency is developing a pilot program to support the earlier diagnosis of upper gastrointestinal cancers, including cancers of the pancreas, stomach, esophagus, gallbladder, and bile ducts. This initiative is being designed in collaboration with health care providers and community partners, with a particular focus on improving access for patients in rural, northern, and Indigenous communities.
 

The pilot will introduce a standardized clinical pathway, including a symptom checklist, to help primary care providers identify patients who may benefit from prompt investigation. The program will support timely access to diagnostic imaging and endoscopy for patients presenting with concerning or persistent symptoms.
 

A key feature of the model is the introduction of a nurse navigator, who will coordinate diagnostic testing, help manage referrals, and support patients through the diagnostic process particularly those facing barriers related to geography, transportation, or access to care.
 

To complement this, the program will also include:

 

• An accredited CME module for providers through the University of Saskatchewan
• Educational tools and resources for patients, communities, and clinicians
   

This pilot is part of a broader effort to reduce delays in diagnosis and improve care coordination. Further details, including the referral process and clinical tools, will be shared as the program is implemented.